Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC.CERO · Entity 8622 | Chief Development Officer | January 07, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERO THERAPEUTICS HOLDINGS, INC.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2036-01-06 | Direct | 1,612,099 |
Reported balance
After 2026-01-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 1,612,099 · Balance 1,612,099 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2026 Filed Jan 9, 2026 16:30 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 1,612,099 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001213900-26-002945 · ownership.xml · derivative · entry 1 Pierce Kristen · CIK 0002039649 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,612,099 Underlying: Common Stock · 1,612,099 shares Expires 2036-01-06 Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 17:01 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 154,841 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001213900-25-050110 · ownership.xml · derivative · entry 1 Pierce Kristen · CIK 0002039649 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,841 Underlying: Common Stock · 154,841 shares Expires 2035-05-29 F1 · derivative.exercise_date: The shares underlying this option shall vest in equal monthly installments through June 4, 2027. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 19:02 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001213900-24-084758 · ownership.xml · derivative · entry 1 Pierce Kristen · CIK 0002039649 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-09-30 F1 · derivative.exercise_date: The shares underlying this option vest in twenty-four (24) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.